{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:10:07Z","timestamp":1783941007430,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Chronic allergic asthma is the result of a T\u2010helper type 2 (Th2)\u2010biased immune status. Current asthma therapies control symptoms in some patients, but a long\u2010lasting therapy has not been established. Anti\u2010Asthma Simplified Herbal Medicine Intervention (ASHMI<jats:sup>\u2122<\/jats:sup>), a Chinese herbal formula improved symptoms and lung function, and reduced Th2 responses in a controlled trial of patients with persistent moderate to severe asthma.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> We evaluated the persistence of ASHMI<jats:sup>\u2122<\/jats:sup> beneficial effects following therapy in a murine model of chronic asthma and the immunological mechanisms underlying such effects.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> BALB\/c mice sensitized intraperitoneally with ovalbumin (OVA) received 3 weekly intratracheal OVA challenges to induce airway hyper\u2010reactivity (AHR) and inflammation (OVA mice). Additionally, OVA mice were treated with ASHMI<jats:sup>\u2122<\/jats:sup> (OVA\/ASHMI<jats:sup>\u2122<\/jats:sup>) or water (OVA\/sham) for 4 weeks, and then challenged immediately and 8 weeks post\u2010therapy. In other experiments, OVA mice received ASHMI<jats:sup>\u2122<\/jats:sup> treatment with concomitant neutralization of IFN\u2010\u03b3 or TGF\u2010\u03b2. Effects on airway responses, cytokine\u2010 and OVA\u2010specific IgE levels were determined 8 weeks post\u2010therapy.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> Before treatment, OVA mice exhibited AHR and pulmonary eosinophilic inflammation following OVA challenge, which was almost completely resolved immediately after completing treatment with ASHMI<jats:sup>\u2122<\/jats:sup> and did not re\u2010occur following OVA re\u2010challenge up to 8 weeks post\u2010therapy. Decreased allergen\u2010specific IgE and Th2 cytokine levels, and increased IFN\u2010\u03b3 levels also persisted at least 8 weeks post\u2010therapy. ASHMI<jats:sup>\u2122<\/jats:sup> effects were eliminated by the neutralization of IFN\u2010\u03b3, but not TGF\u2010\u03b2, during therapy.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> ASHMI<jats:sup>\u2122<\/jats:sup> induced long\u2010lasting post\u2010therapy tolerance to antigen\u2010induced inflammation and AHR. IFN\u2010\u03b3 is a critical factor in ASHMI<jats:sup>\u2122<\/jats:sup> effects.<\/jats:p><jats:p> <jats:italic>Cite this as<\/jats:italic>: K. Srivastava, T. Zhang, N. Yang, H. Sampson and X. M. Li, <jats:italic>Clinical &amp; Experimental Allergy<\/jats:italic>, 2010 (40) 1678\u20131688.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2010.03545.x","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T02:06:34Z","timestamp":1277258794000},"page":"1678-1688","source":"Crossref","is-referenced-by-count":21,"title":["Anti\u2010Asthma Simplified Herbal Medicine Intervention\u2010induced long\u2010lasting tolerance to allergen exposure in an asthma model is interferon\u2010\u03b3, but not transforming growth factor\u2010\u03b2 dependent"],"prefix":"10.1111","volume":"40","author":[{"given":"K.","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1989.tb02408.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70228-3"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15369-X"},{"key":"e_1_2_6_5_2","first-page":"C11","article-title":"Worsening of asthma with systemic corticosteroids","volume":"21","author":"Sheth A","year":"2005","journal-title":"J Gen Intern Med"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051378"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770900902777783"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(86)90315-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","article-title":"Down\u2010regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti\u2010IgE\u2010infusions is reversible in vitro and in vivo","volume":"162","author":"Saini SS","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770900902847727"},{"key":"e_1_2_6_11_2","unstructured":"Early communication about an ongoing safety review of omalizumab (marketed as Xolair). Available athttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm172218.htm(accessed 16 July 2009). FDA. Consum. 9 A.D."},{"key":"e_1_2_6_12_2","first-page":"828","article-title":"Montelukast and emotional well\u2010being as a marker for depression","volume":"122","author":"Holbrook JT","year":"2008","journal-title":"results from 3 randomized, double-masked clinical trials"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328329226f"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.3077"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jf802601j"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.05.029"},{"key":"e_1_2_6_17_2","first-page":"735","article-title":"Safety and tolerability of an antiasthma herbal formula (ASHMI\u2122) in adult asthmatics","volume":"15","author":"Kelly\u2010Pieper K","year":"2009","journal-title":"a randomized, double-blinded, placebo-controlled, dose escalation phase I study"},{"key":"e_1_2_6_18_2","volume-title":"The experimental method of pharmacology","author":"Xiu SY.","year":"1986"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.110102"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02775.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4049\/jimmunol.160.3.1378","article-title":"Induction of pulmonary allergic responses by antigen\u2010specific Th2 cells","volume":"160","author":"Li XM","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.90275.2008"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.062"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-960OC"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.8.4995"},{"key":"e_1_2_6_26_2","first-page":"213","article-title":"Mouse models of allergic asthma","volume":"1","author":"Nials AT","year":"2008","journal-title":"acute and chronic allergen challenge"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076131"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.2.9712018"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-007-7005-6"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00699.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.12.1107"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.12.1172"},{"key":"e_1_2_6_33_2","first-page":"2793","article-title":"Alpha\u2010galactosylceramide\u2010induced iNKT cells suppress experimental allergic asthma in sensitized mice","volume":"35","author":"Hachem P","year":"2005","journal-title":"role of IFN-gamma"},{"key":"e_1_2_6_34_2","first-page":"157","article-title":"T\u2010bet\/GATA\u20103 ratio as a measure of the Th1\/Th2 cytokine profile in mixed cell populations","volume":"278","author":"Chakir H","year":"2003","journal-title":"predominant role of GATA-3"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.11.040"},{"key":"e_1_2_6_36_2","first-page":"755","article-title":"Gandoderma lucidum extract promotes immune responses in normal BALB\/c mice in vivo","volume":"23","author":"Chang YH","year":"2009","journal-title":"In Vivo"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0804481"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.CRJ05008X"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.05.048"},{"key":"e_1_2_6_40_2","first-page":"1128","article-title":"Transforming growth factor\u2010beta in allergic inflammatory disease of the upper airways","volume":"39","author":"Salib RJ","year":"2009","journal-title":"friend or foe?"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.009"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02785.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23792"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01071.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1175OC"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-499OC"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.05.050"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70162-1"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200601-057OC"},{"key":"e_1_2_6_50_2","first-page":"584","article-title":"Therapeutic effects of BCG vaccination in adult asthmatic patients","volume":"88","author":"Choi IS","year":"2002","journal-title":"a randomized, controlled trial"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.12.772"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2010.03545.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2010.03545.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:07:20Z","timestamp":1698779240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2010.03545.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1365-2222.2010.03545.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2010.03545.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}